975 Cornforth Drive
Kent Science Park
Sittingbourne, Kent ME9 8PX
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
Kent Science Park
Sittingbourne, Kent ME9 8PX
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
National Heart & Lung Institute
Sir Alexander Fleming Building
Imperial College, London SW7 2AZ
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
Sir Alexander Fleming Building
Imperial College, London SW7 2AZ
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
The Drug Evaluation Process
IR Pharma capability is based on four main pre-clinical stages that taken together, represent an integrated drug discovery approach.
Target Validation Models
Models provide the means to determine, or confirm, target location and function in rodent tissue, human tissue and cells. This includes:
- Immuno-localisation at tissue and cellular level
- Evaluation of gene expression profiles
- Disease model assessment using knock-out and transgenic animals.
In Vitro Profiling (in rodent and human tissue)
Methodologies to map compound function at a tissue, cellular and molecular level for both human and rodent include:
- Isolated tissue bioassay
- Cellular assays
- Biochemical assays
In Vivo Profiling
Undertaken in both mechanistic and disease models, includes:
- Cellular inflammation and histology
- Functional physiology
- Pharmacodynamic models to establish effective dosing regimens
Clinically relevant biomarkers
Linking laboratory to clinical trials through comparison of control and disease samples in both animal and human studies, utilising:
- Imaging
- Exhaled biomarkers